Shifting Clinical Benchmarks in EGFR-Mutated Non–Small Cell Lung Cancer

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss risk factors guiding frontline therapy decisions in EGFR-mutated NSCLC.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss sequencing strategies in advanced EGFR-mutated NSCLC.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss evolving frontline treatment options in EGFR-mutated non–small cell lung cancer.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss resistance mechanisms in EGFR-mutated NSCLC.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss clinical experience with antibody-drug conjugates in EGFR-mutated NSCLC.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss remaining evidence gaps in EGFR-mutated NSCLC care.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss ongoing research shaping EGFR-mutated NSCLC care.